TrialCancer science2024

Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer.

Xiaofen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.